Trial reportBMC nephrology2012
Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study.
Trial report in BMC nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Recombinant Human Erythropoietin Use in ICU Patients: Does it Prevent Acute Renal Failure?
The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury
Who cites it
24 citing papers in PubMed, 7 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Erythropoiesis-stimulating agents for preventing acute kidney injury.The Cochrane database of systematic reviews · 2024Pooled it
- Effects of interventions targeting the systemic inflammatory response to cardiac surgery on clinical outcomes in adults.The Cochrane database of systematic reviews · 2023Pooled it
- Safety and efficacy of erythropoiesis-stimulating agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis.Intensive care medicine · 2019Pooled it
- Harms of off-label erythropoiesis-stimulating agents for critically ill people.The Cochrane database of systematic reviews · 2017Pooled it
- Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017 : Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine.Intensive care medicine · 2017Pooled it
- Erythropoiesis stimulating agents and reno-protection: a meta-analysis.BMC nephrology · 2017Pooled it
- Efficacy and Safety of Erythropoietin to Prevent Acute Kidney Injury in Patients With Critical Illness or Perioperative Care: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Journal of cardiovascular pharmacology · 2015Pooled it
- Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety.Critical care (London, England) · 2013Trial
- Trial
- Laboratory Analysis of the Renal Function Changes Under Long-Term Exposure to Extremely Low Ambient Temperatures: Case Report.Therapeutic hypothermia and temperature management · 2024Article
- Endocrinological disorders in acute kidney injury: an often overlooked field of clinical research.Journal of nephrology · 2023Review
- Disruption of Kidney-Immune System Crosstalk in Sepsis with Acute Kidney Injury: Lessons Learned from Animal Models and Their Application to Human Health.International journal of molecular sciences · 2022Review
- Strategies for post-cardiac surgery acute kidney injury prevention: A network meta-analysis of randomized controlled trials.Frontiers in cardiovascular medicine · 2022Article
- Targeting the innate repair receptor axisFrontiers in immunology · 2022Article
- Effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratoryClinical kidney journal · 2020Article
- The Effect of Erythropoietin Administration on the Serum Level of YKL-40, pro-BNP and IL-6 in Coronary Surgery Patients.Iranian journal of pharmaceutical research : IJPR · 2020Article
- Cardiac and Vascular Surgery-Associated Acute Kidney Injury: The 20th International Consensus Conference of the ADQI (Acute Disease Quality Initiative) Group.Journal of the American Heart Association · 2018Review
- Erythropoietin stimulates the coronary collateral development in patients with coronary chronic total occlusion.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2016Article
- Bridging translation for acute kidney injury with better preclinical modeling of human disease.American journal of physiology. Renal physiology · 2016Review
- Bridging Translation by Improving Preclinical Study Design in AKI.Journal of the American Society of Nephrology : JASN · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExperimentally, erythropoietin (EPO) has nephroprotective as well as immunomodulatory properties when administered after ischemic renal injury. We tested the hypothesis that different doses of recombinant human EPO administered to patients after cardiac surgery would minimize kidney lesions and the systemic inflammatory response, thereby decreasing acute kidney injury (AKI) incidence.
methodsIn this double-blinded randomized control study, 80 patients admitted to the ICU post-cardiac surgery were randomized by computer to receive intravenously isotonic saline (n = 40) versus α-Epoetin (n = 40): either 40000 IU (n = 20) or 20000 IU (n = 20). The study lasted one year. The primary outcome was the change in urinary NGAL concentration from baseline and 48 h after EPO injection. Creatinine, cystatine C and urinary NGAL levels were measured on the day of randomization and 2-4 days after EPO injection. To assess acute inflammatory response, serum cytokines (IL6 and IL8) were measured at randomization and four days after r-HuEPO injection. Patients and care-takers were blinded for the assignment.
resultsNo patient was excluded after randomization. Patient groups did not differ in terms of age, gender, comorbidities and renal function at randomization. The rate of AKI assessed by AKIN criteria was 22.5% in our population. EPO treatment did not significantly modify the difference in uNGAl between 48 hours and randomization compared to placebo [2.5 ng/ml (-17.3; 22.5) vs 0.7 ng/ml (-31.77; 25.15), p = 0.77] and the incidence of AKI was similar. Inflammatory cytokines levels were not influenced by EPO treatment. Mortality and hospital stays were similar between the groups and no adverse event was recorded.
conclusionIn this randomized-controlled trial, α-Epoetin administrated after cardiac surgery, although safe, demonstrated neither nephroprotective nor anti-inflammatory properties. TRIAL REGISTRATION NUMBER: NCT00676234.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.